Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202216940 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Ina Yoon und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Artificial Intelligence and Biomedical Research, Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Korea. Hauptthemen laut MEDLINE: Amino Acyl-tRNA Synthetases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Drug Development Fund, Ministry of Science and ICT, South Korea, Yonsei University.
Abstract (Originalsprache)
Prolyl‐tRNA synthetase 1 (PARS1) has attracted much interest in controlling pathologic accumulation of collagen containing high amounts of proline in fibrotic diseases. However, there are concerns about its catalytic inhibition for potential adverse effects on global protein synthesis. We developed a novel compound, DWN12088, whose safety was validated by clinical phase 1 studies, and therapeutic efficacy was shown in idiopathic pulmonary fibrosis model. Structural and kinetic analyses revealed that DWN12088 binds to catalytic site of each protomer of PARS1 dimer in an asymmetric mode with different affinity, resulting in decreased responsiveness at higher doses, thereby expanding safety window. The mutations disrupting PARS1 homodimerization restored the sensitivity to DWN12088, validating negative communication between PARS1 promoters for the DWN12088 binding. Thus, this work suggests that DWN12088, an asymmetric catalytic inhibitor of PARS1 as a novel therapeutic agent against fibrosis with enhanced safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Artificial Intelligence and Biomedical Research, Medicinal Bioconvergence Research Center, Yonsei University, Incheon, Korea.
- Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon, Korea.
- Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, Korea.
- Drug Discovery Center, Daewoong Pharmaceutical Co., Ltd, Yongin, Korea.
- Department of Biochemistry, School of Medicine, Catholic University of Daegu, Daegu, Korea.
- College of Medicine, Gangnam Severance Hospital, Yonsei University, Seoul, Korea.
ORCID-Profile: Sinae Oh, Seong Hyeok Cho, Bongyong Lee, Joon Seok Park, Kwang Yeon Hwang, Sunghoon Kim
Förderung
- Korea Drug Development Fund
- Ministry of Science and ICT, South Korea
- Yonsei University
Zitieren
APA
Yoon, I., Kim, S., Cho, M., You, K. A., Son, J., Lee, C., Suh, J. H., Bae, D. J., Kim, J. M., Oh, S., Park, S., Kim, S., Cho, S. H., Park, S., Bang, K., Seo, M., Kim, J. H., Lee, B., Park, J. S., …, & Kim, S. (2023). Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216940
Vancouver
Yoon I, Kim S, Cho M, You KA, Son J, Lee C, et al. Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216940
BibTeX
@article{Yoon2023,
author = {Yoon, Ina and Kim, Sulhee and Cho, Minjae and You, Kyung Ah and Son, Jonghyeon and Lee, Caroline and Suh, Ji Hun and Bae, Da-Jeong and Kim, Jong Min and Oh, Sinae and Park, Songhwa and Kim, Sanga and Cho, Seong Hyeok and Park, Seonha and Bang, Kyuhyeon and Seo, Minjeong and Kim, Jong Hyun and Lee, Bongyong and Park, Joon Seok and Hwang, Kwang Yeon and Kim, Sunghoon},
title = {Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl‐tRNA synthetase 1},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202216940}
}
EUVIMED